Skip to content

Study · Observational study · n = 320 · 2026

6 results

Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.

Postema A, Gaspersz J, Baak BN, Huisman EL, Hoogstraten C, Hagelund LM, Penning-van Beest FJA, Overbeek JA

Diabetes, obesity & metabolism17 Nov 2025Cited by 2 (Europe PMC)

PMID41243611 (opens in a new tab)PMCIDPMC12803591 (opens in a new tab)DOI10.1111/dom.70251 (opens in a new tab)PepBankPUB-41243611
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In GLP-1 receptor agonist-naive adults with type 2 diabetes, HbA1c fell from baseline at 12 months after starting oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, blood sugar (HbA1c) fell from baseline after 12 months on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at 12 months
    Study

    n = 320

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −16.05 mmol/mol
    12 months

    Source sentences

    Summary
    In 320 patients with an average follow-up of 8.1 months the mean (95% confidence interval) change in HbA1c from baseline was -16.05 (-12.57, -19.54) mmol/mol at 12 months, of whom 70% achieved personalized HbA1c targets.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
    Summary · context
    Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12 months of follow-up.
  2. 02HumanObservational studyEfficacy outcome

    In GLP-1 receptor agonist-naive adults with type 2 diabetes, 70% reached personalized HbA1c targets on oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, 70% reached their personal blood sugar target on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePatients reaching personalized HbA1c targets
    Study

    n = 320

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (human).

    Measurements

    Patients achieving personalized HbA1c targets
    70%
    12 months

    Source sentences

    Summary
    In 320 patients with an average follow-up of 8.1 months the mean (95% confidence interval) change in HbA1c from baseline was -16.05 (-12.57, -19.54) mmol/mol at 12 months, of whom 70% achieved personalized HbA1c targets.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
    Summary · context
    Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12 months of follow-up.
  3. 03HumanObservational studyEfficacy outcome

    In GLP-1 receptor agonist-naive adults with type 2 diabetes, body weight fell from baseline at 12 months after starting oral semaglutide.

    In plain wordsIn adults with type 2 diabetes, body weight fell from baseline after 12 months on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 12 months
    Study

    n = 260

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (human).

    Measurements

    Body weight change
    −4.73 kg
    12 months

    Source sentences

    Summary
    Body weight was reduced by -4.73 (-3.63, -5.83) kg at 12 months in 260 patients over an average of 8.2 months follow-up.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
    Summary · context
    Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12 months of follow-up.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes starting oral semaglutide, blood lipid parameters showed minimal change.

    In plain wordsIn adults with type 2 diabetes on oral semaglutide, blood fat levels changed very little.

    Peptide
    Semaglutide
    Outcome
    No significant changeBlood lipid parameters
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Minimal changes were observed in blood lipid parameters and diastolic blood pressure, with moderate changes in systolic blood pressure.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
    Summary · context
    Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12 months of follow-up.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes starting oral semaglutide, diastolic blood pressure showed minimal change.

    In plain wordsIn adults with type 2 diabetes on oral semaglutide, diastolic blood pressure changed very little.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiastolic blood pressure
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Minimal changes were observed in blood lipid parameters and diastolic blood pressure, with moderate changes in systolic blood pressure.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
    Summary · context
    Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12 months of follow-up.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes starting oral semaglutide, systolic blood pressure showed moderate changes; the direction is not stated.

    In plain wordsIn adults with type 2 diabetes on oral semaglutide, systolic blood pressure showed moderate changes.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · oral · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Minimal changes were observed in blood lipid parameters and diastolic blood pressure, with moderate changes in systolic blood pressure.
    2 context sentences
    Summary · context
    Glucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
    Summary · context
    Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12 months of follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.